|
|
血清CA125相关参数在上皮性卵巢癌化疗敏感性及预后预测方面的研究进展
|
Abstract:
本文综述了血清CA125相关参数在上皮性卵巢癌化疗敏感性及预后预测方面的研究现状及进展。首先，介绍了血清CA125检测在上皮性卵巢癌化疗敏感性预测及预后预测领域的背景及重要性。接着，通过对国内外相关文献的梳理和分析，详细阐述了术前CA125水平、血清CA125最低值、血清CA125半衰期、GCIG CA125应答、CA125消除速率常数K值(即KELIM)这五个基于上皮性卵巢癌治疗过程中血清CA125变化发展而来的参数的研究现状及其特点。通过总结以往研究及文献发现，目前各项血清CA125相关参数在预测上皮性卵巢癌化疗敏感性及预后方面皆有不足，主要表现在计算方式复杂及截断值不一致，CA125消除速率常数K值(即KELIM)是近年来出现的一个较稳定及经济便携的预后预测指标，可以为未来上皮性卵巢癌预后预测模型建立提供一个新的参考，并为后续研究提供一些思路和建议。
This article summarizes the current research status and advancements in the use of serum CA125-related parameters for predicting chemotherapy sensitivity and prognosis in epithelial ovarian cancer. Firstly, it introduces the background and importance of serum CA125 detection in predicting chemotherapy sensitivity and prognosis for epithelial ovarian cancer. Subsequently, through a review and analysis of relevant domestic and international literature, the research status and characteristics of five parameters derived from serum CA125 changes during the treatment of epithelial ovarian cancer are elaborated in detail: preoperative CA125 levels, nadir CA125 levels, CA125 half-life, GCIG CA125 response, and the CA125 elimination rate constant K value (KELIM). By summarizing previous studies and literature, it is found that the current serum CA125-related parameters have limitations in predicting chemotherapy sensitivity and prognosis for epithelial ovarian cancer, mainly manifested in complex calculation methods and inconsistent cutoff values. Among these, the CA125 elimination rate constant K value (KELIM) is a relatively stable, economical, and portable prognostic indicator that has emerged in recent years. It can provide a new reference for the establishment of future prognostic prediction models for epithelial ovarian cancer and offer some ideas and suggestions for subsequent research.
| [1] | Baandrup, L., Dehlendorff, C., Hertzum-Larsen, R., Hannibal, C.G. and Kjaer, S.K. (2021) Prognostic Impact of Socioeconomic Status on Long-Term Survival of Non-Localized Epithelial Ovarian Cancer—The Extreme Study. Gynecologic Oncology, 161, 458-462. https://doi.org/10.1016/j.ygyno.2021.01.042 |
| [2] | 冯艳玲, 刘继红. 肿瘤化疗敏感度预测及临床应用进展[J]. 中国实用妇科与产科杂志, 2010, 26(8): 636-640. |
| [3] | Kang, S., Kim, T., Nam, B., Seo, S., Kim, B., Bae, D., et al. (2009) Preoperative Serum CA‐125 Levels and Risk of Suboptimal Cytoreduction in Ovarian Cancer: A Meta‐Analysis. Journal of Surgical Oncology, 101, 13-17. https://doi.org/10.1002/jso.21398 |
| [4] | 刘浚源, 刘原, 张祎, 等. 糖类抗原125动力学变化在卵巢癌初次肿瘤细胞减灭术患者预后评估中的应用研究[J]. 中国实用妇科与产科杂志, 2023, 39(5): 547-551. |
| [5] | Cooper, B., Sood, A.K., Davis, C.S., Ritchie, J.M., Sorosky, J.I., Anderson, B., et al. (2002) Preoperative CA125 Levels: An Independent Prognostic Factor for Epithelial Ovarian Cancer. Obstetrics & Gynecology, 100, 59-64. https://doi.org/10.1016/s0029-7844(02)02057-4 |
| [6] | Crawford, S.M. and Peace, J. (2005) Does the Nadir CA125 Concentration Predict a Long-Term Outcome after Chemotherapy for Carcinoma of the Ovary? Annals of Oncology, 16, 47-50. https://doi.org/10.1093/annonc/mdi012 |
| [7] | Prat, A., Parera, M., Peralta, S., Perez-Benavente, M.A., Garcia, A., Gil-Moreno, A., et al. (2008) Nadir CA-125 Concentration in the Normal Range as an Independent Prognostic Factor for Optimally Treated Advanced Epithelial Ovarian Cancer. Annals of Oncology, 19, 327-331. https://doi.org/10.1093/annonc/mdm495 |
| [8] | Zeng, J., Huang, H., Shan, Y., Li, Y., Jin, Y. and Pan, L. (2017) The Effect of CA125 Nadir Level on Survival of Advanced-Stage Epithelial Ovarian Carcinoma after Interval Debulking Surgery. Journal of Cancer, 8, 3410-3415. https://doi.org/10.7150/jca.21362 |
| [9] | Piatek, S., Panek, G., Lewandowski, Z., Piatek, D., Kosinski, P. and Bidzinski, M. (2021) Nadir CA-125 Has Prognostic Value for Recurrence, but Not for Survival in Patients with Ovarian Cancer. Scientific Reports, 11, Article No. 18190. https://doi.org/10.1038/s41598-021-97564-1 |
| [10] | Čolaković, S., Lukiç, V., Mitroviç, L., Jeliç, S., Susnjar, S. and Marinkoviç, J. (2000) Prognostic Value of CA125 Kinetics and Half-Life in Advanced Ovarian Cancer. The International Journal of Biological Markers, 15, 147-152. https://doi.org/10.1177/172460080001500204 |
| [11] | 连利娟. 林巧稚妇科肿瘤学[M]. 第4版. 北京: 人民卫生出版社, 2006: 437-440. |
| [12] | 张立英, 葛宜枝, 顾祥, 等. 血清CA125半衰期与晚期卵巢癌铂类耐药及预后的相关性研究[J]. 南通大学学报(医学版), 2017, 37(3): 289-291. |
| [13] | Riedinger, J.M., Eche, N., Basuyau, J.P., Dalifard, I., Hacene, K. and Pichon, M.F. (2008) Prognostic Value of Serum CA125 Bi-Exponential Decrease during First Line Paclitaxel/Platinum Chemotherapy: A French Multicentric Study. Gynecologic Oncology, 109, 194-198. https://doi.org/10.1016/j.ygyno.2008.01.035 |
| [14] | Gadducci, A., Zola, P., Landoni, F., Maggino, T., Sartori, E., Bergamino, T., et al. (1995) Serum Half-Life of CA125 during Early Chemotherapy as an Independent Prognostic Variable for Patients with Advanced Epithelial Ovarian Cancer: Results of a Multicentric Italian Study. Gynecologic Oncology, 58, 42-47. https://doi.org/10.1006/gyno.1995.1181 |
| [15] | Gadducci, A., Cosio, S., Fanucchi, A., Negri, S., Cristofani, R. and Genazzani, A.R. (2004) The Predictive and Prognostic Value of Serum CA125 Half-Life during Paclitaxel/Platinum-Based Chemotherapy in Patients with Advanced Ovarian Carcinoma. Gynecologic Oncology, 93, 131-136. https://doi.org/10.1016/j.ygyno.2003.12.043 |
| [16] | Mano, A., Godinho, I. and Falcão, A.C. (2005) CA125 Half‐Life Breakpoint between a “Good” and “Poor” Prognosis in Patients with Ovarian Cancer. International Journal of Gynecology & Obstetrics, 88, 333-335. https://doi.org/10.1016/j.ijgo.2004.12.028 |
| [17] | 周颖, 钱莉莉, 朱晨辰, 等. 上皮性卵巢癌CA125半衰期与器官转移聚类的相关性分析[J]. 现代妇产科进展, 2020, 29(4): 250-255. |
| [18] | Ledermann, J.A., Raja, F.A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N. and Sessa, C. (2013) Newly Diagnosed and Relapsed Epithelial Ovarian Carcinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Annals of Oncology, 24, vi24-vi32. https://doi.org/10.1093/annonc/mdt333 |
| [19] | Riedinger, J.M. (2007) Prognostic Value of CA125 Half-Life and Early Normalization during Chemotherapy in Advanced Ovarian Tumors: Results of a Multicentric French Study. Bulletin du Cancer, 94, 287-295. |
| [20] | Alexander, M., Beattie‐Manning, R., Blum, R., Byrne, J., Hornby, C., Kearny, C., et al. (2016) Guidelines for Timely Initiation of Chemotherapy: A Proposed Framework for Access to Medical Oncology and Haematology Cancer Clinics and Chemotherapy Services. Internal Medicine Journal, 46, 964-969. https://doi.org/10.1111/imj.13157 |
| [21] | Rustin, G.J., Nelstrop, A.E., McClean, P., Brady, M.F., McGuire, W.P., Hoskins, W.J., et al. (1996) Defining Response of Ovarian Carcinoma to Initial Chemotherapy According to Serum CA125. Journal of Clinical Oncology, 14, 1545-1551. https://doi.org/10.1200/jco.1996.14.5.1545 |
| [22] | Rustin, G.J.S., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., et al. (2011) Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA125 Agreed by the Gynecological Cancer Intergroup (GCIG). International Journal of Gynecologic Cancer, 21, 419-423. https://doi.org/10.1097/igc.0b013e3182070f17 |
| [23] | Lee, C.K., Friedlander, M., Brown, C., Gebski, V.J., Georgoulopoulos, A., Vergote, I., et al. (2011) Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. JNCI: Journal of the National Cancer Institute, 103, 1338-1342. https://doi.org/10.1093/jnci/djr282 |
| [24] | Morgan, R.D., McNeish, I.A., Cook, A.D., James, E.C., Lord, R., Dark, G., et al. (2021) Objective Responses to First-Line Neoadjuvant Carboplatin-Paclitaxel Regimens for Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (ICON8): Post-Hoc Exploratory Analysis of a Randomised, Phase 3 Trial. The Lancet Oncology, 22, 277-288. https://doi.org/10.1016/s1470-2045(20)30591-x |
| [25] | Clamp, A.R., James, E.C., McNeish, I.A., Dean, A., Kim, J., O'Donnell, D.M., et al. (2019) Weekly Dose-Dense Chemotherapy in First-Line Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Treatment (ICON8): Primary Progression Free Survival Analysis Results from a GCIG Phase 3 Randomised Controlled Trial. The Lancet, 394, 2084-2095. https://doi.org/10.1016/s0140-6736(19)32259-7 |
| [26] | Wilbaux, M., Hénin, E., Oza, A., Colomban, O., Pujade-Lauraine, E., Freyer, G., et al. (2014) Prediction of Tumour Response Induced by Chemotherapy Using Modelling of CA-125 Kinetics in Recurrent Ovarian Cancer Patients. British Journal of Cancer, 110, 1517-1524. https://doi.org/10.1038/bjc.2014.75 |
| [27] | You, B., Harvey, R., Henin, E., Mitchell, H., Golfier, F., Savage, P.M., et al. (2013) Early Prediction of Treatment Resistance in Low-Risk Gestational Trophoblastic Neoplasia Using Population Kinetic Modelling of hCG Measurements. British Journal of Cancer, 108, 1810-1816. https://doi.org/10.1038/bjc.2013.123 |
| [28] | Wilbaux, M., Hénin, E., Oza, A., Colomban, O., Pujade-Lauraine, E., Freyer, G., et al. (2014) Dynamic Modeling in Ovarian Cancer: An Original Approach Linking Early Changes in Modeled Longitudinal CA-125 Kinetics and Survival to Help Decisions in Early Drug Development. Gynecologic Oncology, 133, 460-466. https://doi.org/10.1016/j.ygyno.2014.04.003 |
| [29] | You, B.M., Colomban, O., Tod, M., Ray-Coquard, I.L., Lortholary, A., Hardy-Bessard, A.C., et al. (2016) The Predictive Value of the CA-125 Modeled Kinetic Parameter KELIM Is Validated in 3 Independent Datasets (AGO-OVAR 7&9; ICON 7 AGO/GINECO/GCIG Trials). Annals of Oncology, 27, vi296. https://doi.org/10.1093/annonc/mdw374.04 |
| [30] | You, B., Colomban, O., Heywood, M., Lee, C., Davy, M., Reed, N., et al. (2013) The Strong Prognostic Value of KELIM, a Model-Based Parameter from CA125 Kinetics in Ovarian Cancer: Data from CALYPSO Trial (A GINECO-GCIG Study). Gynecologic Oncology, 130, 289-294. https://doi.org/10.1016/j.ygyno.2013.05.013 |
| [31] | Colomban, O., Tod, M., Leary, A., Ray-Coquard, I., Lortholary, A., Hardy-Bessard, A.C., et al. (2019) Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study. Clinical Cancer Research, 25, 5342-5350. https://doi.org/10.1158/1078-0432.ccr-18-3335 |
| [32] | You, B., Sehgal, V., Hosmane, B., Huang, X., Ansell, P.J., Dinh, M.H., et al. (2023) CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis from the VELIA/GOG-3005 Study. Journal of Clinical Oncology, 41, 107-116. https://doi.org/10.1200/jco.22.00430 |
| [33] | Lauby, A., Colomban, O., Corbaux, P., Peron, J., Van Wagensveld, L., Gertych, W., et al. (2021) The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review. Cancers, 14, Article 98. https://doi.org/10.3390/cancers14010098 |
| [34] | You, B., Robelin, P., Tod, M., Louvet, C., Lotz, J., Abadie-Lacourtoisie, S., et al. (2020) CA-125 Elimination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. Clinical Cancer Research, 26, 4625-4632. https://doi.org/10.1158/1078-0432.ccr-20-0054 |
| [35] | Corbaux, P., You, B., Glasspool, R.M., Yanaihara, N., Tinker, A.V., Lindemann, K., et al. (2023) Survival and Modelled Cancer Antigen-125 ELIMination Rate Constant K Score in Ovarian Cancer Patients in First-Line before Poly(ADP-Ribose) Polymerase Inhibitor Era: A Gynaecologic Cancer Intergroup Meta-Analysis. European Journal of Cancer, 191, Article 112966. https://doi.org/10.1016/j.ejca.2023.112966 |
| [36] | Kim, J.H., Cho, H., Park, E.Y., Han, K., Kim, E.T., Lee, J., et al. (2023) Prognostic Value of CA125 Kinetics, Half-Life, and Nadir in the Treatment of Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis. International Journal of Gynecologic Cancer, 33, 1913-1920. https://doi.org/10.1136/ijgc-2023-004825 |
| [37] | Matsukuma, K., Nishio, S., Tasaki, S., Park, J., Nasu, H., Yoshimitsu, T., et al. (2023) Association of Chemotherapy Response Score with Multidrug Resistance 1 and CA125 Elimination Rate Constant K in Patients with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy. The Kurume Medical Journal, 70, 29-37. https://doi.org/10.2739/kurumemedj.ms7012004 |
| [38] | Bouvarel, B., Colomban, O., Frenel, J., Loaec, C., Bourgin, C., Berton, D., et al. (2024) Clinical Impact of CA-125 Elimination Rate Constant K (KELIM) on Surgical Strategy in Advanced Serous Ovarian Cancer Patients. International Journal of Gynecologic Cancer, 34, 574-580. https://doi.org/10.1136/ijgc-2023-004872 |
| [39] | Li, C., Cui, Q., Wang, X., Yao, S., Tu, H. and Chen, M. (2024) CA-125 Elimination Rate Constant K (KELIM) as a Promising Predictor of Complete Cytoreduction after Neoadjuvant Chemotherapy in Advanced Ovarian Cancer Patients: A Retrospective Study from Two Chinese Hospitals. BMC Cancer, 24, Article No. 609. https://doi.org/10.1186/s12885-024-12252-3 |
| [40] | Colomban, O., Tod, M., Peron, J., Perren, T.J., Leary, A., Cook, A.D., et al. (2020) Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates among High-Risk Disease Patients (ICON-7). JNCI Cancer Spectrum, 4, pkaa026. https://doi.org/10.1093/jncics/pkaa026 |
| [41] | You, B., Fleming, G., Bookman, M., Moore, K., Steffensen, K. and Coleman, R. (2020) 36 Prognostic Value and Association with Veliparib Benefit of Modeled CA-125 Elimination Kinetics (KELIM) in Patients with Newly Diagnosed Ovarian Cancer: Analysis from the VELIA/GOG-3005 Study. International Journal of Gynecological Cancer, 30, A24-A25. https://doi.org/10.1136/ijgc-2020-igcs.36 |
| [42] | Labidi-Galy, S.I., de La Motte Rouge, T., Derbel, O., Wolfer, A., Kalbacher, E., Olivier, T., et al. (2019) Clinical Factors Associated with Prolonged Response and Survival under Olaparib as Maintenance Therapy in BRCA Mutated Ovarian Cancers. Gynecologic Oncology, 155, 262-269. https://doi.org/10.1016/j.ygyno.2019.09.008 |
| [43] | Fong, P.C., Yap, T.A., Boss, D.S., Carden, C.P., Mergui-Roelvink, M., Gourley, C., et al. (2010) Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating with Platinum-Free Interval. Journal of Clinical Oncology, 28, 2512-2519. https://doi.org/10.1200/jco.2009.26.9589 |
